Atrial natriuretic peptide before and after cardioversion of persistent atrial fibrillation;Kardiowersja elektryczna a stȩżenie przedsionkowego peptydu natriuretycznego u chorych z przetrwałym migotaniem przedsionków

Kardiologia Polska

Volumn 58, Issue 4, 2003, Pages 255-262

  Wozakowska Kapłon, Beata ^a,c   Opolski, Grzegorz ^b   Janion, Marianna ^a  

^a Regional District Hospital   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Swietokrzyskie Centrum Kardiologii Poland   (Poland)

Author keywords

Atrial fibrillation; Atrial natriuretic peptide; Cardioversion

Indexed keywords

ATRIAL NATRIURETIC FACTOR;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

EID: 0038416710     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kannel W.B., Abbott R.D., Savage D.D.: Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N. Engl. J. Med. 1982, 306, 1018-1022.
2. Rossi A., Enriquez-Sarano M., Burnett J.C. et al.: Natriuretic peptide levels in atrial fibrillation. J. Am. Coll. Cardiol. 2000, 35, 1256-1262.
3. Arad M., Shotan A., Weinberger A. et al.: Plasma atrial natriuretic peptide levels for predicting the outcome of atrial fibrillation. Cardiology 2001, 95, 74-79.
4. Suzuki T., Yamazaki T., Yazaki Y.: The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res. 2001, 51, 481-488.
5. Wożakowska-Kapłon B., Opolski G., Kosior D. et al.: An increase in plasma atrial natriuretic peptide concentration during exercise predicts a successful cardioversion and maintenance of sinus rhythm in patients with chronic atrial fibrillation. PACE 2000, 23 (Pt.II), 1876-1879.
6. Langenickel T., Pagel I., Hohnel K. et al.: Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 2000, 278, H1500-H1506.
7. Groban L., Cowley A.W.J., Ebert T.J.: Atrial natriuretic peptide augments forearm capillary filtration in humans. Am. J. Physiol. 1990, 259, H258-H263.
8. Brunner-La Rocca H.P., Kiowski W., Ramsay D. et al.: Therapeutic benefits of increasing natriuretic peptide levels. Cardiovasc. Res. 2001, 51, 510-520.
9. Levin E.R., Gardner D. G., Samson W.K.: Mechanisms of disease: Natriuretic peptides. N. Engl. J. Med. 1998, 339, 321-328.
10. Benedict C.R., Johnstone D.E., Weiner D.E. et al.: Relation of neurohormonal activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. 1994, 23, 1410-1420.
11. De Bold A.J., Bruneau B.G., Kuroski de Bold M.L.: Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 1996, 31, 7-18.
12. Raine A.E., Erne P., Burgisser E. et al.: P Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 1986, 315, 533-537.
13. Bie P., Wang B.C., Leadley Jr R.J. et al.: Haemodynamic and renal effects of low dose infusions of atrial peptide in awake dogs. Am. J. Physiol. 1988, 254, R 161-169.
14. Roy D., Paillard F., Cassidy D. et al.: Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J. Am. Coll. Cardiol. 1987, 9, 509-514.
15. Arakawa M., Miwa H., Kambara K. et al.: Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am. J. Cardiol. 1992, 70, 550-552.
16. Petersen P., Kastrup J., Vilhelmsen H. et al.: Atrial natriuretic peptide in atrial fibrillation before and after electrical cardioversion therapy. Eur. Heart J. 1988, 9, 639-641.
17. Mookherjee S., Anderson G., Smulyan H. et al.: Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am. J. Cardiol. 1991, 67, 377-380.
18. Arakawa M., Miwa H., Noda T. et al.: Alterations in atrial natriuretic peptide release after DC cardioversion of non-valvular chronic atrial fibrillation. Eur. Heart J. 1995, 16, 977-985.
19. Appleton C.P., Galloway J.M., Gonzales M.S. et al.: Estimation of left ventricular filling pressures using two-dimensional and Doppler echocardiography in adult patients with cardiac disease. J. Am. Coll. Cardiol. 1993, 22, 1972-1982.
20. Takeichi N., Fukuda N., Tamura Y. et al.: Relationship between left atrial function and plasma level of atrial natriuretic peptide in patients with heart disease. Cardiology 1998, 90, 13-19.
21. Berglund H., Boukter S., Theodorsson E. et al.: Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. Br. Heart J. 1990, 64, 9-13.
22. Rossi A., Enriquez-Sarano M., Burnett J.C. et al.: Natriuretic peptide levels in atrial fibrillation. A prospective hormonal and Doppler-echocardiographic study. J. Am. Coll. Cardiol. 2000, 35, 1256-1262.
23. Skinner N.S. Jr, Mitchell J.H., Wallace A.G. et al.: Hemodynamic consequences of atrial fibrillation at constant ventricular rates. Am. J. Med. 1964, 36, 342-350.
24. Ellenbogen K.A., Rogers R., Walsh M. et al.: Increased circulating atrial natriuretic factor (ANF) release during induced ventricular tachycardia. Am. Heart J. 1988, 116, 1233-1238.